CREMα suppresses spleen tyrosine kinase expression in normal but not systemic lupus erythematosus T cells

Arthritis and Rheumatism

Volumn 64, Issue 3, 2012, Pages 799-807

  Ghosh, Debjani ^a   Kis Toth, Katalin ^a   Juang, Yuang Taung ^a   Tsokos, George C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT MODULATOR; CYCLIC AMP RESPONSIVE ELEMENT MODULATOR ALPHA; PROTEIN KINASE SYK; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EPIGENETICS; GEL MOBILITY SHIFT ASSAY; GENE OVEREXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ACETYLATION; ACETYLTRANSFERASES; BASE SEQUENCE; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CYCLIC AMP RESPONSE ELEMENT MODULATOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; GENE SILENCING; HISTONES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOLECULAR SEQUENCE DATA; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SPLEEN; T-LYMPHOCYTES; TRANSFECTION;

EID: 84857760849     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.33375     Document Type: Article

References (36)

1. Rudd CE,. Adaptors and molecular scaffolds in immune cell signaling. Cell 1999; 96: 5-8.
2. Sada K, Takano T, Yanagi S, Yamamura H,. Structure and function of SYK protein-tyrosine kinase. J Biochem 2001; 130: 177-86.
3. Palacios EH, Weiss A,. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004; 23: 7990-8000.
4. Chu P, Pardo J, Zhao H, Li CC, Pali E, Shen MM, et al. Systematic identification of regulatory proteins critical for T-cell activation. J Biol 2003; 2: 21.
5. Krishnan S, Warke VG, Nambiar MP, Tsokos GC, Farber DL,. The FcRγ subunit and SYK kinase replace the CD3ζ-chain and ZAP-70 kinase in the TCR signaling complex of human effector CD4 T cells. J Immunol 2003; 170: 4189-95.
6. Kadlecek TA, van Oers NS, Lefrancois L, Olson S, Finlay D, Chu DH, et al. Differential requirements for ZAP-70 in TCR signaling and T cell development. J Immunol 1998; 161: 4688-94.
7. Couture C, Baier G, Altman A, Mustelin T,. p56lck-independent activation and tyrosine phosphorylation of p72SYK by T-cell antigen receptor/CD3 stimulation. Proc Natl Acad Sci U S A 1994; 91: 5301-5.
8. Chan AC, van Oers NS, Tran A, Turka L, Law CL, Ryan JC, et al. Differential expression of ZAP-70 and SYK protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling. J Immunol 1994; 152: 4758-66.
9. Tsokos GC, Nambiar MP, Tenbrock K, Juang YT,. Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE. Trends Immunol 2003; 24: 259-63.
10. Juang YT, Wang Y, Jiang G, Peng HB, Ergin S, Finnell M, et al. PP2A dephosphorylates Elf-1 and determines the expression of CD3ζ and FcRγ in human systemic lupus erythematosus T cells. J Immunol 2008; 181: 3658-64.
11. Krishnan S, Kiang JG, Fisher CU, Nambiar MP, Nguyen HT, Kyttaris VC, et al. Increased caspase-3 expression and activity contribute to reduced CD3ζ expression in systemic lupus erythematosus T cells. J Immunol 2005; 175: 3417-23.
12. Krishnan S, Juang YT, Chowdhury B, Magilavy A, Fisher CU, Nguyen H, et al. Differential expression and molecular associations of SYK in systemic lupus erythematosus T cells. J Immunol 2008; 181: 8145-52.
13. Montminy M,. Transcriptional regulation by cyclic AMP. Annu Rev Biochem 1997; 66: 807-2.
14. Matthews RP, Guthrie CR, Wailes LM, Zhao X, Means AR, McKnight GS,. Calcium/calmodulin-dependent protein kinase types II and IV differentially regulate CREB-dependent gene expression. Mol Cell Biol 1994; 14: 6107-16.
15. Loriaux MM, Brennan RG, Goodman RH,. Modulatory function of CREB-CREMα heterodimers depends upon CREMα phosphorylation. J Biol Chem 1994; 269: 28839-43.
16. Tenbrock K, Juang YT, Tolnay M, Tsokos GC,. The cyclic adenosine 5′-monophosphate response element modulator suppresses IL-2 production in stimulated T cells by a chromatin-dependent mechanism. J Immunol 2003; 170: 2971-6.
17. Tenbrock K, Juang YT, Leukert N, Rith J, Tsokos GC,. The transcriptional repressor cAMP response element modulator α interacts with histone deacetylase 1 to repress promoter activity. J Immunol 2006; 177: 6159-64.
18. Tenbrock K, Kyttaris VC, Ahlmann M, Ehrchen JM, Tolnay M, Melkonyan H, et al. The cyclic AMP response element modulator regulates transcription of the TCR ζ-chain. J Immunol 2005; 175: 5975-80.
19. Mishra N, Khan IU, Tsokos GC, Kammer GM,. Association of deficient type II protein kinase A activity with aberrant nuclear translocation of RIIβ subunit in systemic lupus erythematosus T lymphocytes. J Immunol 2000; 165: 2830-40.
20. Juang YT, Wang Y, Solomou EE, Li Y, Mawrin C, Tenbrock K, et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest 2005; 115: 996-1004.
21. Foulkes NS, Borrelli E, Sassone-Corsi P,. CREM gene: use of alternative DNA-binding domains generates multiple antagonists of cAMP-induced transcription. Cell 1991; 64: 739-49.
22. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
23. Dignam JD, Lebovitz RM, Roeder RG,. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983; 11: 1475-89.
24. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang DH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.
25. Deng GM, Liu L, Bahjat FR, Pine PR, Tsokos GC,. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum 2010; 62: 2086-92.
26. Patel DR, Richardson BC,. Epigenetic mechanisms in lupus. Curr Opin Immunol 2010; 22: 478-82.
27. Richardson BC,. Primer: epigenetics of autoimmunity. Nat Clin Pract Rheumatol 2007; 3: 521-7.
28. Zhao S, Long H, Lu Q,. Epigenetic perspectives in systemic lupus erythematosus: pathogenesis, biomarkers, and therapeutic potentials. Clin Rev Allergy Immunol 2010; 39: 3-9.
29. + T cells. J Autoimmun 2010; 35: 58-69.
30. Garcia BA, Busy SA, Shabanowitz J, Hunt DF, Mishra N,. Resetting the epigenetic histone code in the MRL-lpr/lpr mouse model of lupus by histone deacetylase inhibition. J Proteome Res 2005; 4: 2032-42.
31. Privalsky ML,. Depudecin makes a debut. Proc Natl Acad Sci U S A 1998; 95: 3335-7.
32. Li B, Carey M, Workman JL,. The role of chromatin during transcription. Cell 2007; 128: 707-19.
33. Bird A, Jaenisch R,. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003; 33: 245-54.
34. Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS,. Histone deacetylase inhibitors modulate renal disease in MRL-lpr/lpr mouse. J Clin Invest 2003; 111: 539-52.
35. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB,. An oral spleen tyrosine kinase (SYK) inhibitor for rheumatoid arthritis. N Engl J Med 2010; 363: 1303-12.
36. Tsokos GC,. Systemic lupus erythematosus [review]. N Engl J Med 2011; 365: 2110-21.